Case report: A challenging case of stage IVB mixed neuroendocrine-non-neuroendocrine neoplasm of the gallbladder treated with extended radical resection including portal vein reconstruction - Report - MDSpire

Case report: A challenging case of stage IVB mixed neuroendocrine-non-neuroendocrine neoplasm of the gallbladder treated with extended radical resection including portal vein reconstruction

  • By

  • Quanlei Wang

  • Shun Ruan

  • Xiyin Ye

  • Haifeng Wang

  • Quli Zeng

  • Xiao Luo

  • Kai Guo

  • Ailing Zhang

  • Huixiang Huang

  • Gang Wu

  • Haibo Chen

  • Suhui Zeng

  • Tiansheng Xie

  • Wanhong Liang

  • Weihong Duan

  • Sangui Wang

  • June 8, 2026

  • 0 min

Share

Clinical Report: A Complex Instance of Stage IVB Mixed Neoplasm of the Gallbladder

Overview

This report details a rare case of a 78-year-old female with a mixed neuroendocrine-non-neuroendocrine neoplasm of the gallbladder, successfully managed through extensive radical resection. The case highlights the importance of multidisciplinary collaboration in diagnosing and treating such aggressive tumors.

Background

Gallbladder cancer is a highly lethal malignancy, often diagnosed at advanced stages due to non-specific symptoms. Mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN), particularly those with large cell neuroendocrine carcinoma components, are extremely rare and aggressive. Understanding the clinical characteristics and treatment strategies for these tumors is crucial for improving patient outcomes.

Data Highlights

The patient had a carcinoembryonic antigen (CEA) level of 84.09 ng/ml and underwent extensive radical surgery, including partial hepatectomy and portal vein reconstruction. Postoperative pathology confirmed a mixed adenoma-large cell neuroendocrine carcinoma with negative surgical margins.

Key Findings

  • The patient was diagnosed with a gallbladder mass during a routine examination.
  • Imaging revealed malignancy with liver and lymph node metastases.
  • Postoperative pathology confirmed a mixed adenoma-large cell neuroendocrine carcinoma.
  • Immunohistochemistry showed high Ki-67 proliferation index (approximately 80%).
  • All surgical margins were negative post-resection.

Clinical Implications

This case underscores the potential for aggressive surgical intervention in selected patients with advanced gallbladder cancer. The findings contribute to the limited literature on MiNEN, emphasizing the need for careful diagnosis and treatment planning.

Conclusion

The successful management of this rare case through extensive surgical resection highlights the importance of multidisciplinary approaches in treating complex gallbladder neoplasms. Further validation of oncological benefits is necessary.

Related Resources & Content

  1. Favorable long-term outcomes following concurrent resection of the esophagus, stomach, and pancreas, 2008 -- Springer
  2. Left Extended Hepatectomy with Biliary Resection and Reconstruction for Hilar Cholangiocarcinoma, 2025 -- Springer
  3. Outcomes of Oncologic Extended Resection for Gallbladder Cancer, 2025 -- ASCO Post
  4. Neuroendocrine Neoplasms of the Gastrointestinal Tract, 2023 -- PMC
  5. IHPBA-APHPBA clinical practice guidelines for gallbladder cancer, 2024 -- Amsterdam UMC
  6. R0 Two-Stage Hepatectomy with Portal Vein Ligation: Advancing Treatment for Patients with Extensive Bilobular Colorectal Liver Metastases
  7. Classification and rarity of MiNEN, 2024 -- PMC
  8. Surgical consensus for gallbladder carcinoma, 2024 -- IHPBA-APHPBA
  9. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer - PMC
  10. Techniques of Oncovascular Reconstruction of Portal and Mesenteric Veins during Pancreatic and Hepatobiliary Surgery
  11. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial - PubMed
  12. Four-year survival and safety analysis from the Phase 3 TOPAZ-1 study of durvalumab plus chemotherapy in biliary tract cancer
  13. ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer - PMC
  14. Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology - PubMed

Original Source(s)

Related Content